The findings of recent clinical trials reporting that recombinant erythropoietin (rEPO) therapy in some cancer patients may negatively impact recurrence-free survival have raised concerns regarding potential adverse direct effects of erythropoietin in tumors, such as stimulation of the proliferation of cancer cells and/or tumor angiogenesis [8]–[11]. The gene discussed is EPO; the disease is cancer.